Overview

Efficacy and Safety Study of Ultra-early Mobile Stroke Unit Neuroprotection Combined With Revascularization for Acute Ischemic Stroke (EXCELLENT)

Status:
RECRUITING

Trial end date:
2027-07-31

Target enrollment:

Participant gender:

Summary

EXCELLENT was a prospective, multicenter, randomized, double-blind, placebo-controlled clinical study in which participants were randomized participants were randomized (1:1) to receive either IV thrombolysis + edaravone or IV thrombolysis + matched placebo (same volume of tablets without drug components), and the primary outcome was the proportion of patients with transformed bleeding on MRI at 72 hours following revascularization therapy.

Phase:

PHASE4

Details

Lead Sponsor:

Ruijun Ji

Collaborators:

Nanjing Baixinyu Pharmaceutical Co., Ltd.
Nanyang nanshi Hospital
Suzhou First People's Hospital
Xing'an League People's Hospital

Treatments:

Control Groups
Edaravone
Fibrinolytic Agents